Concepedia

Aurélien Voissière

AV

Statistics

Publications

8

Citations

190

H-Index

8

Active since

2016

Affiliations

Inserm(Current)

Université Clermont Auvergne

Centre National de la Recherche Scientifique

Imagerie Moléculaire et Stratégies Théranostiques

Centre Léon Bérard

Aurélien Voissière is an author at Inserm specializing in oncology, tumor-activated prodrugs, and prodrug design.

ORCID

Publications per year

2016–2025

8

Publications

8

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers

Aurélien Voissière, Carlos Gomez‐Roca, Sylvie Chabaud et al. · Science Translational Medicine · 2024 · 54 citations

, , +17

Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing

Aurélien Voissière, E. Jouberton, Elise Maubert et al. · PLoS ONE · 2017 · 50 citations · Full text

, , +11

Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma

Donia Ghedira, Aurélien Voissière, Caroline Peyrode et al. · European Journal of Medicinal Chemistry · 2018 · 17 citations · Full text

, , +15

Type III interferon primes pDCs for TLR7 activation and antagonizes immune suppression mediated by TGF-β and PGE2

Candice Sakref, Alexis Saby, Céline Rodriguez et al. · Nature Communications · 2025 · 16 citations · Full text

, , +17

Interleukin-35 impairs human NK cell effector functions and induces their ILC1-like conversion with tissue residency features

Valentin Picant, Lara Revol-Bauz, Laurie Tonon et al. · Nature Communications · 2025 · 15 citations · Full text

, , +15

1–5 of 8